- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
- Interventions
- VLS-1488
- Drug
- Lead sponsor
- Volastra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 8,003
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2 Low Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride
- Drug · Procedure
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Malignant Neoplasm of Bone and Articular Cartilage, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasm of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract, Melanoma and Other Malignant Neoplasms of Skin
- Interventions
- Gemcitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 50 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioma
- Interventions
- M032
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 36 Months and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- PF-06427878, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pain Management, Opioid Use, Prostate Cancer
- Interventions
- Oxycodone, Acetaminophen, Ketamine, Ketorolac
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 40 Years to 75 Years · Male only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Fasting, Delayed Gastric Emptying, Aspiration Pneumonia, Respiratory Aspiration of Gastric Content
- Interventions
- Gastric Ultrasound Baseline Scans, Acetaminophen Absorption Test (AAT), Gastric Ultrasound Serial Scans
- Diagnostic Test
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Eye-tracking
- Interventions
- EYE-SYNC eye-tracking device, SCAT-3, Desktop Eye-Tracker
- Device · Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
- Interventions
- SBP-101, nab-paclitaxel, Gemcitabine Injection
- Drug
- Lead sponsor
- Panbela Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- La Jolla, California • Gainesville, Florida • Rochester, New York
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- DYNE-101, Placebo
- Drug
- Lead sponsor
- Dyne Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 8
- States / cities
- Stanford, California • Gainesville, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Healthy Volunteers, Chronic Kidney Disease
- Interventions
- IGT-303, Placebo
- Drug
- Lead sponsor
- Ingenia Therapeutics INC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Lakeland, Florida • Statesville, North Carolina + 1 more
- Conditions
- Smoking Cessation
- Interventions
- SBP-9330, Placebo
- Drug
- Lead sponsor
- Camino Pharma, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Advanced Solid Tumors
- Interventions
- Treatment with ARQ 197 in combination with gemcitabine
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Sarcopenia, Frailty, Aging
- Interventions
- MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
- Drug
- Lead sponsor
- TNF Pharmaceuticals, Inc.
- Industry
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
- Conditions
- Peritoneal Cancer, Pseudomyxoma Peritonei, Mucinous Adenocarcinoma, Mucinous Tumor, Colorectal Cancer, Gastric Cancer, Primary Peritoneal Carcinoma, Mesothelioma
- Interventions
- nanoliposomal irinotecan
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Lexington, Kentucky • Stony Brook, New York
- Conditions
- Multiple Sclerosis
- Interventions
- PF-06342674 0.25 mg/kg, Placebo, PF-06342674 1.5 mg/kg, PF-06342674 6.0 mg/kg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Albany, New York • Latham, New York • Cleveland, Ohio + 2 more
- Conditions
- Non-Small Cell Lung Cancer, Venous Thromboembolism
- Interventions
- Combination of Arixtra with chemotherapy
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Advanced Solid Tumor
- Interventions
- M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
- Conditions
- SARS-CoV-2, Influenza
- Interventions
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 1,758 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 69
- States / cities
- Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
- Conditions
- Bladder Cancer
- Interventions
- modified resectoscope, TURBT
- Device · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumor
- Interventions
- PEEL-224, FOLF+B
- Drug
- Lead sponsor
- Peel Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more
- Conditions
- Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
- Interventions
- Selinexor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Ovarian Cancer, Malignant Neoplasm of Uterus
- Interventions
- Sacituzumab, Cisplatin
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Cancer
- Interventions
- ZIO-201-T and doxorubicin
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Houston, Texas